Kristijonas Žemaitis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristijonas Žemaitis has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Agatheeswaran Subramaniam
Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
5 shared publications - Jonas Larsson
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
4 shared publications - Alexandra Bäckström
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications - David Yudovich
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications - Jenny Hansson
Division of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications Natsumi Miharada
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications
Latest Publications
- Open Access
- 13 December 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (24) , 7407-7417
Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. To elucidate regulatory mechanisms governing the maintenance and propagation of human HSCs ex vivo, we screened libraries of annotated small molecules in human cord blood cells using an optimized assay for detection of functional HSCs during culture. We found that the antifungal agent ciclopirox ethanolamine (CPX) selectively supported immature CD34+CD90+ cells during culture and enhanced their long-term in vivo repopulation capacity. Purified HSCs treated with CPX showed a reduced cell division rate and an enrichment of HSC-specific gene expression patterns. Mechanistically, we found that the HSC stimulating effect of CPX was directly mediated by chelation of the intracellular iron pool, which in turn affected iron-dependent proteins and enzymes mediating cellular metabolism and respiration. Our findings unveil a significant impact of iron homeostasis in regulation of human HSCs, with important implications for both basic HSC biology and clinical hematology.
- 13 December 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (24) , 7407-7417
Open AccessCiclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. To elucidate regulatory mechanisms governing the maintenance and propagation of human HSCs ex vivo, we screened libraries of annotated small molecules in human cord blood cells using an optimized assay for detection of functional HSCs during culture. We found that the antifungal agent ciclopirox ethanolamine (CPX) selectively supported immature CD34+CD90+ cells during culture and enhanced their long-term in vivo repopulation capacity. Purified HSCs treated with CPX showed a reduced cell division rate and an enrichment of HSC-specific gene expression patterns. Mechanistically, we found that the HSC stimulating effect of CPX was directly mediated by chelation of the intracellular iron pool, which in turn affected iron-dependent proteins and enzymes mediating cellular metabolism and respiration. Our findings unveil a significant impact of iron homeostasis in regulation of human HSCs, with important implications for both basic HSC biology and clinical hematology.
- Open Access
- 29 March 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (5) , 104662
The stem cell–supporting small molecule UM171 triggers Cul3-KBTBD4–mediated degradation of ELM2 domain–harboring proteins
- 29 March 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (5) , 104662
Open AccessThe stem cell–supporting small molecule UM171 triggers Cul3-KBTBD4–mediated degradation of ELM2 domain–harboring proteins
- Open Access
- 28 August 2022
- Published by Elsevier in Experimental Hematology
- Vol. 115, 20-29
RNAi Screen Identifies MTA1 as an Epigenetic Modifier of Differentiation Commitment in Human HSPCs
- 28 August 2022
- Published by Elsevier in Experimental Hematology
- Vol. 115, 20-29
Open AccessRNAi Screen Identifies MTA1 as an Epigenetic Modifier of Differentiation Commitment in Human HSPCs
- 17 March 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (11) , 1659-1669
Genome-wide association study on 13 167 individuals identifies regulators of blood CD34+cell levels
Stem cell transplantation is a cornerstone in the treatment of blood malignancies. The most common method to harvest stem cells for transplantation is by leukapheresis, requiring mobilization of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the blood. Identifying the genetic factors that control blood CD34+ cell levels could reveal new drug targets for HSPC mobilization. Here we report the first large-scale, genome-wide association study on blood CD34+ cell levels. Across 13 167 individuals, we identify 9 significant and 2 suggestive associations, accounted for by 8 loci (PPM1H, CXCR4, ENO1-RERE, ITGA9, ARHGAP45, CEBPA, TERT, and MYC). Notably, 4 of the identified associations map to CXCR4, showing that bona fide regulators of blood CD34+ cell levels can be identified through genetic variation. Further, the most significant association maps to PPM1H, encoding a serine/threonine phosphatase never previously implicated in HSPC biology. PPM1H is expressed in HSPCs, and the allele that confers higher blood CD34+ cell levels downregulates PPM1H. Through functional fine-mapping, we find that this downregulation is caused by the variant rs772557-A, which abrogates an MYB transcription factor–binding site in PPM1H intron 1 that is active in specific HSPC subpopulations, including hematopoietic stem cells, and interacts with the promoter by chromatin looping. Furthermore, PPM1H knockdown increases the proportion of CD34+ and CD34+90+ cells in cord blood assays. Our results provide the first large-scale analysis of the genetic architecture of blood CD34+ cell levels and warrant further investigation of PPM1H as a potential inhibition target for stem cell mobilization.
- 17 March 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (11) , 1659-1669
Genome-wide association study on 13 167 individuals identifies regulators of blood CD34+cell levels
Stem cell transplantation is a cornerstone in the treatment of blood malignancies. The most common method to harvest stem cells for transplantation is by leukapheresis, requiring mobilization of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the blood. Identifying the genetic factors that control blood CD34+ cell levels could reveal new drug targets for HSPC mobilization. Here we report the first large-scale, genome-wide association study on blood CD34+ cell levels. Across 13 167 individuals, we identify 9 significant and 2 suggestive associations, accounted for by 8 loci (PPM1H, CXCR4, ENO1-RERE, ITGA9, ARHGAP45, CEBPA, TERT, and MYC). Notably, 4 of the identified associations map to CXCR4, showing that bona fide regulators of blood CD34+ cell levels can be identified through genetic variation. Further, the most significant association maps to PPM1H, encoding a serine/threonine phosphatase never previously implicated in HSPC biology. PPM1H is expressed in HSPCs, and the allele that confers higher blood CD34+ cell levels downregulates PPM1H. Through functional fine-mapping, we find that this downregulation is caused by the variant rs772557-A, which abrogates an MYB transcription factor–binding site in PPM1H intron 1 that is active in specific HSPC subpopulations, including hematopoietic stem cells, and interacts with the promoter by chromatin looping. Furthermore, PPM1H knockdown increases the proportion of CD34+ and CD34+90+ cells in cord blood assays. Our results provide the first large-scale analysis of the genetic architecture of blood CD34+ cell levels and warrant further investigation of PPM1H as a potential inhibition target for stem cell mobilization.
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (19) , 2151-2161
Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood–derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (19) , 2151-2161
Open AccessLysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood–derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.
- Open Access
- 17 August 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (35) , 21267-21273
Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws
Significance: Primary stem cells are difficult to transfect, and their viability and function are impaired by traditional transfection methods. We show that nanostraws can be used to deliver RNA to primary human hematopoietic stem cells without any detectable negative effects. Nanostraw-treated cells show no alterations in gene expression and fully retain their proliferative capacity and their potential to regenerate blood cells of different lineages in vivo. This nonperturbative transfection method can benefit functional studies and clinical applications where minimal impact on stem cell function and viability is required.
- 17 August 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (35) , 21267-21273
Open AccessEfficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws
Significance: Primary stem cells are difficult to transfect, and their viability and function are impaired by traditional transfection methods. We show that nanostraws can be used to deliver RNA to primary human hematopoietic stem cells without any detectable negative effects. Nanostraw-treated cells show no alterations in gene expression and fully retain their proliferative capacity and their potential to regenerate blood cells of different lineages in vivo. This nonperturbative transfection method can benefit functional studies and clinical applications where minimal impact on stem cell function and viability is required.